More Early Stocks in Motion
Waters Corp.
(WAT) - Get Report
cut its first-quarter earnings forecast to a range of 34 cents to 37 cents a share, down from its previous estimate of 44 cents a share. The company said it now expects revenue growth in the range of 3% to 4%, compared with its pervious forecast of 13%. The stock was down $1.97, or 4.25%, to $44.29 after hours.
Beazer Homes
(BZH) - Get Report
said it will take a non-cash goodwill impairment charge for the underperforming operations in certain states. The company said the amount of the charge will be finalized and logged as a non-cash item in results for the second quarter ending March 31. Beazer maintained its forecast for fiscal 2005 earnings of $6.67 to $7 a share, excluding impairment charges. The stock was down 65 cents, or 1.3%, to $49.40 after the close.
Micron
(MU) - Get Report
announced better-than-expected earnings for the second quarter ended March 3 of $117.9 million, or 17 cents a share, compared to a loss of $28.3 million, or 4 cents a share, a year ago. Revenue for the second quarter was $1.3 billion. Analysts expected 15 cents a share on sales of $1.22 billion, according to Thomson First Call. The stock was up 25 cents, or 2.47%, to $10.37 after the close.
Encore Medical
(ENMC)
announced that the Food and Drug Administration has granted premarket clearance for its reverse-shoulder prosthesis. The device provides surgeons with an alternative to conventional shoulder prosthesis to address patients with an irreparable, severely torn or deficient rotator cuff. The stock was up 42 cents, or 7.8%, to $5.81 in after-hours trading.
Pfizer
(PFE) - Get Report
announced that it has obtained a preliminary injunction halting the sales of generic quinapril marketed by
Teva
(TEVA) - Get Report
and Ranbaxy Labs. A U.S. district court ordered Teva and Ranbaxy to immediately stop marketing the product. Shares of Pfizer were up 16 cents, or 0.6%, to $25.80, while Teva was down 90 cents, or 2.9%, to $29.60, in after-hours trading.